Laurel Venture Capital

Laurel Venture Capital is a life science focused venture capital firm with a focus on investment in early and mid-stage therapeutic assets of life science companies in China, Europe and the United States. Laurel' s team of investors and entrepreneurs share a passion for the transformative power of technology to fulfil the unmet medical need, and to fund companies that can deliver breakthrough medical advances with cutting-edge technology and strong IP profiles. We have a strong team of professionals and external consultants with extensive experience in finance, regulatory, IP, CMC, pre-clinical and clinical operations that engages strategically with our portfolio company Boards, management teams and co-investors to help secure successful corporate partnerships and exits.

1 past transactions

HemaCell

Series A in 2022
Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish a platform using platelet cells as a drug delivery carrier.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.